(Q45773011)

15 December 2017

title

Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis (English)

1 reference

15 December 2017

0 references

4

1 reference

15 December 2017

David E. Szymkowski

7

1 reference

15 December 2017

Jan L Ceuppens

object named as

Jan L Ceuppens

8

0 references

Gert Van Assche

6

object named as

Gert Van Assche

1 reference

15 December 2017

5

Paul Rutgeerts

1 reference

15 December 2017

1

Clémentine Perrier

1 reference

15 December 2017

author name string

Gert de Hertogh

2

1 reference

15 December 2017

Jonathan Cremer

3

1 reference

15 December 2017

publication date

1 February 2013

1 reference

15 December 2017

Inflammatory Bowel Diseases

published in

1 reference

15 December 2017

volume

19

1 reference

15 December 2017

issue

2

1 reference

15 December 2017

page(s)

246-253

1 reference

15 December 2017

Inflammatory bowel disease

cites work

1 reference

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

Adverse effects of biologics used for treating IBD.

21 January 2018

1 reference

Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents

21 January 2018

1 reference

Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation.

21 January 2018

1 reference

Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB.

21 January 2018

1 reference

Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity.

21 January 2018

1 reference

Membrane tumor necrosis factor confers partial protection to Listeria infection

21 January 2018

1 reference

Contribution of transmembrane tumor necrosis factor to host defense against Mycobacterium bovis bacillus Calmette-guerin and Mycobacterium tuberculosis infections.

21 January 2018

1 reference

Membrane TNF confers protection to acute mycobacterial infection

21 January 2018

1 reference

Anti-TNF-α Agents in the Treatment of Immune-Mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls

21 January 2018

1 reference

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

21 January 2018

1 reference

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action

21 January 2018

1 reference

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

Inhibition of Thl responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells

21 January 2018

1 reference

Inactivation of TNF signaling by rationally designed dominant-negative TNF variants

21 January 2018

1 reference

Evaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver disease

21 January 2018

1 reference

CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner.

21 January 2018

1 reference

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activation-induced cell death.

21 January 2018

1 reference

Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination

21 January 2018

1 reference

Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis

21 January 2018

1 reference

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

21 January 2018

1 reference

A systematic review of the off-label use of biological therapies in systemic autoimmune diseases

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.23023

1 reference

15 December 2017

1 reference

15 December 2017